MoonLake Immunotherapeutics MLTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's retained earnings?
- MoonLake Immunotherapeutics (MLTX) reported retained earnings of -$532.62M in Q1 2026.
- How has MoonLake Immunotherapeutics's retained earnings changed year-over-year?
- MoonLake Immunotherapeutics's retained earnings decreased by 93.3% year-over-year, from -$275.54M to -$532.62M.
- What is the long-term trend for MoonLake Immunotherapeutics's retained earnings?
- Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's retained earnings has grown at a 183.8% compound annual growth rate (CAGR), from -$2.52M to -$462.91M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.